Form 4: Supernus Pharmaceuticals CFO Reports Stock Transaction
Insider Transaction (Form 4)
Timothy C Dec, Senior Vice-President & CFO of Supernus Pharmaceuticals, Inc., reported multiple transactions in common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 1,250 Common Stock on August 12, 2026; holds 9,733 after (Direct).
- Tax/exercise-price withholding: disposed of 604 Common Stock at $46.57 ($28,128) on August 12, 2026; holds 9,129 after (Direct).
- Option exercise/conversion: disposed of 1,250 Performance Share Unit on August 12, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Timothy C Dec — Officer (Senior Vice-President & CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 1,250 | — | — | 9,733 |
| 2026-08-12 | Tax/exercise-price withholding | Common Stock | 604 | $47 | $28.1K | 9,129 |
| 2026-08-12 | Option exercise/conversion | Performance Share Unit | 1,250 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (1,250 shares) |
| 2026-08-12 | Tax/exercise-price withholding (604 shares) |
| 2026-08-12 | Option exercise/conversion (1,250 shares) |
Keywords
insider transaction, Form 4, SUPN, SUPERNUS PHARMACEUTICALS, INC., neutral, Timothy C Dec
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.